Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Sell
31
MREO Quote, Financials, Valuation and Earnings
Last price:
$2.56
Seasonality move
:
-12.15%
Day range:
$2.55 - $2.63
52-week range:
$2.25 - $5.02
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.48x
Volume:
702.7K
Avg. volume:
1.3M
1-year change:
-17.42%
Market cap:
$397.2M
Revenue:
$10M
EPS (TTM):
-$0.30
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$0.01 | 1109.31% | -69.36% | $7.89 |
|
AUTL
Autolus Therapeutics PLC
|
$3M | -$0.24 | -61.82% | -46.14% | $10.40 |
|
BCYC
Bicycle Therapeutics PLC
|
$5.5M | -$0.85 | -55.59% | -31.65% | $29.55 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -- | -- | -- | -- |
|
VRNA
Verona Pharma PLC
|
$33.5M | -$0.15 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
$2.56 | $7.89 | $397.2M | -- | $0.00 | 0% | -- |
|
AUTL
Autolus Therapeutics PLC
|
$1.68 | $10.40 | $445.8M | -- | $0.00 | 0% | -- |
|
BCYC
Bicycle Therapeutics PLC
|
$9.49 | $29.55 | $656.7M | -- | $0.00 | 0% | 15.65x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$2.00 | $17.97 | $1.3M | -- | $0.00 | 0% | 1.80x |
|
TCBP
TC BioPharm (Holdings) PLC
|
$1.62 | -- | $831.1K | -- | $0.25 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$66.09 | $81.00 | $5.6B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | 0.564 | -- | -- |
|
AUTL
Autolus Therapeutics PLC
|
-- | 3.987 | -- | 17.97x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 0.789 | -- | 13.61x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 0.756 | -- | 1.20x |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -1.548 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | -0.759 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MREO
Mereo BioPharma Group PLC
|
-- | -$9.1M | -- | -- | -- | -$7.5M |
|
AUTL
Autolus Therapeutics PLC
|
-- | -$67.7M | -80.74% | -80.74% | -331.28% | -$86.3M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$67.1M | -25.48% | -26.21% | -1426.21% | -$9.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
TCBP
TC BioPharm (Holdings) PLC
|
-- | -$2.6M | -- | -- | -- | -$3.5M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Mereo BioPharma Group PLC vs. Competitors
-
Which has Higher Returns MREO or AUTL?
Autolus Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -522.15%. Mereo BioPharma Group PLC's return on equity of -- beat Autolus Therapeutics PLC's return on equity of -80.74%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- AUTLAutolus Therapeutics PLC-- -$0.31 $582M -
What do Analysts Say About MREO or AUTL?
Mereo BioPharma Group PLC has a consensus price target of $7.89, signalling upside risk potential of 208.06%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $10.40 which suggests that it could grow by 520.9%. Given that Autolus Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Autolus Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is MREO or AUTL More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 2.067, suggesting its more volatile than the S&P 500 by 106.723%.
-
Which is a Better Dividend Stock MREO or AUTL?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or AUTL?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $10.1M. Mereo BioPharma Group PLC's net income of -$15M is higher than Autolus Therapeutics PLC's net income of -$82.1M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M AUTLAutolus Therapeutics PLC-- -- $10.1M -$82.1M
-
Which has Higher Returns MREO or BCYC?
Bicycle Therapeutics PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -1398.44%. Mereo BioPharma Group PLC's return on equity of -- beat Bicycle Therapeutics PLC's return on equity of -26.21%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M -
What do Analysts Say About MREO or BCYC?
Mereo BioPharma Group PLC has a consensus price target of $7.89, signalling upside risk potential of 208.06%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $29.55 which suggests that it could grow by 211.33%. Given that Bicycle Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 BCYCBicycle Therapeutics PLC5 3 0 -
Is MREO or BCYC More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.121, suggesting its more volatile than the S&P 500 by 12.137%.
-
Which is a Better Dividend Stock MREO or BCYC?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BCYC?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $3.7M. Mereo BioPharma Group PLC's net income of -$15M is higher than Bicycle Therapeutics PLC's net income of -$51.9M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 15.65x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M BCYCBicycle Therapeutics PLC15.65x -- $3.7M -$51.9M
-
Which has Higher Returns MREO or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About MREO or BDRX?
Mereo BioPharma Group PLC has a consensus price target of $7.89, signalling upside risk potential of 208.06%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 804.58%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is MREO or BDRX More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.
-
Which is a Better Dividend Stock MREO or BDRX?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or BDRX?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$15M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus 1.80x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M BDRXBiodexa Pharmaceuticals PLC1.80x -- -- --
-
Which has Higher Returns MREO or TCBP?
TC BioPharm (Holdings) PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of --. Mereo BioPharma Group PLC's return on equity of -- beat TC BioPharm (Holdings) PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- TCBPTC BioPharm (Holdings) PLC-- -$5.07 -- -
What do Analysts Say About MREO or TCBP?
Mereo BioPharma Group PLC has a consensus price target of $7.89, signalling upside risk potential of 208.06%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 2862.96%. Given that TC BioPharm (Holdings) PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe TC BioPharm (Holdings) PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 TCBPTC BioPharm (Holdings) PLC0 0 0 -
Is MREO or TCBP More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock MREO or TCBP?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.25 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or TCBP?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than TC BioPharm (Holdings) PLC quarterly revenues of --. Mereo BioPharma Group PLC's net income of -$15M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M TCBPTC BioPharm (Holdings) PLC-- -- -- -$2.5M
-
Which has Higher Returns MREO or VRNA?
Verona Pharma PLC has a net margin of -- compared to Mereo BioPharma Group PLC's net margin of -92.29%. Mereo BioPharma Group PLC's return on equity of -- beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital MREOMereo BioPharma Group PLC-- -$0.10 -- VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About MREO or VRNA?
Mereo BioPharma Group PLC has a consensus price target of $7.89, signalling upside risk potential of 208.06%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 22.56%. Given that Mereo BioPharma Group PLC has higher upside potential than Verona Pharma PLC, analysts believe Mereo BioPharma Group PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings MREOMereo BioPharma Group PLC6 0 0 VRNAVerona Pharma PLC5 0 0 -
Is MREO or VRNA More Risky?
Mereo BioPharma Group PLC has a beta of 0.973, which suggesting that the stock is 2.723% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.392, suggesting its less volatile than the S&P 500 by 60.803%.
-
Which is a Better Dividend Stock MREO or VRNA?
Mereo BioPharma Group PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mereo BioPharma Group PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MREO or VRNA?
Mereo BioPharma Group PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Mereo BioPharma Group PLC's net income of -$15M is higher than Verona Pharma PLC's net income of -$33.8M. Notably, Mereo BioPharma Group PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mereo BioPharma Group PLC is -- versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MREOMereo BioPharma Group PLC-- -- -- -$15M VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
95
EXOD alert for Mar 21
Exodus Movement [EXOD] is up 17.89% over the past day.
Buy
58
SIG alert for Mar 21
Signet Jewelers [SIG] is down 0.64% over the past day.
Sell
43
HQY alert for Mar 21
HealthEquity [HQY] is up 0.28% over the past day.
